http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Yihai Liu,Mingyue Wu,Chongxia Zhong,Biao Xu,Lina Kang 한국생체재료학회 2022 생체재료학회지 Vol.26 No.2
Aims: The alternatively activated macrophages have shown a cardioprotective effect in heart failure. However, the effect of M2 adoptive transfer in non-ischemic heart failure is unknown. In this study, we evaluated the efficacy of M-CSF plus IL-4 induced M2-like macrophages transplantation in doxorubicin-induced cardiotoxicity. Methods: Bone marrow mononuclear cells were polarized as CCR2+CD206+ M2-like macrophages by a combination of M-CSF plus IL-4 treatment. C57BL/6 mice received a single intraperitoneal njection of doxorubicin (15 mg/kg). The treatment group were treated with M2-like macrophages (1 × 10^6 cells per mouse; i.v.) once a week for 2 weeks. After 3 weeks, we examined the percentage of resident cells and cardiac function. Furthermore, we evaluated cardiac fibrosis, cardiomyocyte apoptosis and circulating inflammatory factors. Finally, we investigated the mitochondria transfer in vitro in a direct and indirect co-culture conditions. Results: Cardiac function was significantly improved in doxorubicin-induced heart failure by adoptive transfer of M2-like macrophages. Besides, M2-like macrophages treatment attenuated cardiac fibrosis and cardiomyocyte apoptosis, as well as increased the level of circulating IL-4 and Th2 response. In vitro, M2-like macrophages could transfer mitochondria to injured cardiomyocytes in a direct and indirect way. Conclusions: In our study, adoptive transfer of M2-like macrophages could protect against the doxorubicin-induced cardiotoxicity, which may be partly attributed to mitochondria transfer. And M2-like macrophages transplantation could become a treatment for non-ischemic heart failure in the clinical practice.
Bingchuan Yan,Xiaojing Huang,Kai Chen,Hui Liu,Shanshan Wei,Yihai Wu,Li Wang 한국공업화학회 2021 Journal of Industrial and Engineering Chemistry Vol.100 No.-
Amoxicillin (AMX) is the most commonly used antibiotic in life. AMX was extracted from aqueoussolution by synergetic carrier emulsion liquid membrane (ELM) technology for thefirst time. Themembrane phase of ELM was mainly composed of kerosene and butyl acetate. The carrier has consisted ofAliquat-336 and TOA, the surfactant was Span-80, and the membrane enhancer was liquid paraffin. AndNa2CO3 and NaCl were used as the internal aqueous phase for extraction. Firstly, the basic structure andmechanism of emulsion were characterized and analyzed. And then, the center composite design (CCD)of response surface methodology (RSM) was used to optimize the operating conditions. The optimalvalues were: Aliquat-336 concentration (1.1% v/v), trioctylamine (TOA) concentration (8.6% v/v), andextraction time (15 min), AMX concentration (75 mg/L). A polynomial model wasfitted to predict theextraction yield of AMX. Under the optimal operating conditions, the optimal extraction prediction valuewas 98.58%, the extraction actual value was 98.2%, and the recovery rate of AMX was 75.3%.